Home/ Stocks/ ENTX

Entera Bio Ltd. Ordinary Shares

ENTX XNAS

$1.03 -0.06 (-5.50%) ▼ 15-min delayed

Open

$1.05

High

$1.10

Low

$1.03

Volume

99.6K

Market Cap

$49.98M

About Entera Bio Ltd. Ordinary Shares

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 22 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-3,200,000	$0.07
Q2 2025	$0	$-2,656,000	$0.06
Q1 2025	$42.0K	$-2,567,000	$0.06
FY 2024	$181.0K	$-9,541,000	$0.25

Related Market News

No specific coverage for ENTX yet. Check out our latest market news or earnings calendar.

Get ENTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Entera Bio Ltd. Ordinary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.